This Month in Psychopharmacology

New Research Links Depression to Increased Risk of Multiple Chronic Diseases

Mood disorders are increasingly viewed as whole-body conditions aff...

Read More

Rheumatoid Arthritis Linked to Faster Cognitive Decline in Dementia Patient

Rheumatoid arthritis (RA) has been linked to an increased risk of d...

Read More

Study Demonstrates Success in Shifting Adolescent Sleep Patterns Through Targeted Interventions

A recent study examined whether a motivational group-based sleep in...

Read More

FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment

The FDA recently approved. AXS-07 is an oral, rapidly absorbed, mul...

Read More

New Insights into Esketamine Treatment: Efficacy, Safety, and Long-Term Effects

Intranasal esketamine has been approved as an adjunctive pharmacoth...

Read More

Deprescribing Antidepressants in Children and Adolescents

When considering the discontinuation of antidepressant treatment, f...

Read More

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

A recent randomized clinical trial provides promising evidence that...

Read More

Population Study Reveals Most Effective Antipsychotic Strategies for First-Episode Schizophrenia

A recent population-based cohort study examined the effectiveness o...

Read More

Social Determinants of Health and Suicide-Related Outcomes

Over 700,000 deaths annually are attributable to suicide. While psy...

Read More

Associations Between Biomarkers of Inflammation and Depressive Symptoms

A recent study published in Translational Psychiatry has provided ...

Read More

Depressive Symptoms and Amyloid Pathology

A recent large-scale study examined the association between depress...

Read More

Label Update for Viloxazine ER: New Pharmacodynamic Data and Breastfeeding Info

The FDA has approved an update for the label for viloxazine ER to n...

Read More